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Abstract
Introduction: Prothrombin complex concentrates (PCC) are haemostatic blood preparations indicated for urgent
anticoagulation reversal, though the optimal dose for effective reversal is still under debate. The latest generation
of PCCs include four coagulation factors, the so-called 4-factor PCC. The aim of this study was to compare the
efficacy and safety of two doses, 25 and 40 IU/kg, of 4-factor PCC in vitamin K antagonist (VKA) associated
intracranial haemorrhage.
Methods: We performed a phase III, prospective, randomised, open-label study including patients with objectively
diagnosed VKA-associated intracranial haemorrhage between November 2008 and April 2011 in 22 centres in
France. Patients were randomised to receive 25 or 40 IU/kg of 4-factor PCC. The primary endpoint was the
international normalised ratio (INR) 10 minutes after the end of 4-factor PCC infusion. Secondary endpoints were
changes in coagulation factors, global clinical outcomes and incidence of adverse events (AEs).
Results: A total of 59 patients were randomised: 29 in the 25 IU/kg and 30 in the 40 IU/kg group. Baseline
demographics and clinical characteristics were comparable between the groups. The mean INR was significantly
reduced to 1.2 - and ≤1.5 in all patients of both groups - 10 minutes after 4-factor PCC infusion. The INR in the 40
IU/kg group was significantly lower than in the 25 IU/kg group 10 minutes (P = 0.001), 1 hour (P = 0.001) and 3
hours (P = 0.02) after infusion. The 40 IU/kg dose was also effective in replacing coagulation factors such as PT (P =
0.038), FII (P = 0.001), FX (P <0.001), protein C (P = 0.002) and protein S (0.043), 10 minutes after infusion. However,
no differences were found in haematoma volume or global clinical outcomes between the groups. Incidence of
death and thrombotic events was similar between the groups.
Conclusions: Rapid infusion of both doses of 4-factor PCC achieved an INR of 1.5 or less in all patients with a
lower INR observed in the 40 IU/kg group. No safety concerns were raised by the 40 IU/kg dose. Further trials are
needed to evaluate the impact of the high dose of 4-factor PCC on functional outcomes and mortality.
Trial registration: Eudra CT number 2007-000602-73.
Introduction
Strong evidence supports the use of oral anticoagulant
therapy (OAT) in primary and secondary prophylaxis of
venous thromboembolism and in patients with prothrom-
botic factors such as atrial fibrillation and prosthetic heart
valves [1,2]. An estimated 1 to 1.5% of the western
population has undergone OAT, including mainly vitamin
K antagonists (VKA), following the publication of guide-
lines in favour of anticoagulation [3,4].
However, VKAs carry a significant risk of life-threaten-
ing haemorrhage including intracerebral and subdural
haemorrhage. Thirty-day acute mortality for VKA-asso-
ciated intracranial haemorrhage is high, ranging from 40
to 60% [5]. Most survivors are neurologically impaired and
suffer from severe disability [6,7]. Haematoma volume and
lower level of consciousness are major determinants of a
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poor prognosis in these patients [7,8] and up to 50% of
patients develop secondary volume enlargement [9].
Timely medical management of VKA-associated intra-
cranial haemorrhage, including immediate discontinuation
and rapid reversal of the anticoagulant therapy, is crucial
to improve patient prognosis by reducing haematoma
growth [10]. OAT reversal is achieved by replacing
depleted coagulation factors by using fresh frozen plasma
(FFP) or prothrombin complex concentrate (PCC) and by
administering vitamin K. The goal of these measures is to
decrease the international normalised ratio (INR) values to
≤1.4 and preferably ≤1.2 [10-17].
Four of the current guidelines recommend PCC rather
than FFP as the first-choice treatment to increase levels
of vitamin K-dependent coagulation factors [10-18]. A
review of the published literature found that PCCs,
compared to FFP, were more effective in shortening the
time to INR correction and were associated with a low
risk of thrombotic adverse events [19,20].
A recent meta-analysis including 1,032 patients supports
the safety of PCC in patients with VKA-associated intra-
cranial haemorrhage and reports an incidence of throm-
boembolic events of 1.4% (95% CI, 0.8 to 2.1) [21]. The
safety and efficacy of PCC were also demonstrated by the
rapid infusion speed in these patients [22-24].
The early PCC composition contained three coagulation
factors II, IX and X, with no or very little amount of factor
VII. However, newer formulations, available in some
European countries, include normal amounts of factor VII
and are thus known as ‘four-factor concentrates’ or ‘4-fac-
tor PCCs’. The optimal dose of PCC for OAT reversal has
not yet been established. Doses ranging between 25 and
50 international units (IU)/kg have been recommended,
since 1 IU/kg raises factors II, IX and × levels by about 1%
and a 30 to 50% increase in factors levels are usually
considered sufficient to achieve haemostasis [13].
Recent results suggest that higher doses could provide
clinical benefit in terms of INR normalization and subse-
quently in term of clinical outcomes, without increasing
the risk of thromboembolic complications [23]. The aim of
this randomised study was to compare the efficacy and
safety of two dose regimens of 4-factor PCC, 25 and 40 IU/
Kg, in emergency reversal of anticoagulation in patients
with intracranial haemorrhage.
Materials and methods
Overall design and study plan
This phase III, multicentre, randomised, open-label study
included two parallel groups and was conducted in 22 cen-
tres in France. Of these, 16 centres enrolled at least one
patient. This study was conducted in compliance with the
Helsinki Declaration. The protocol was submitted for
approval to an ethics committee and to the French drug
regulatory body (AFSSAPS- French Agency for Health
Product Safety). Ethics and regulatory approvals were
obtained before the start of inclusions. The necessary writ-
ten informed consent was obtained for all patients
involved in the study, including consent to publish.
Study population
Patients were eligible for inclusion if they had an objec-
tively diagnosed OAT-associated cerebral haemorrhage
(computed tomography or magnetic resonance). Other
inclusion criteria were age ≥18 years and written informed
consent. When a patient was unable to sign the informed
consent, consent was obtained from a legal representative
or a family member. Exclusion criteria were deep coma on
admission (Glasgow Coma Scale (GCS) 3 to 5), generalised
seizure, acute sepsis, crush injury or disseminated intravas-
cular coagulation, high risk of thrombosis (pulmonary
embolism or phlebitis during the last three months), con-
comitant disability (modified Rankin scale (mRS) >2),
patients having received vitamin K prior to admission to
the investigational centre, known allergy to vitamin K,
hypersensitivity to the active substances of 4-factor PCC
(human coagulation factors II, VII, IX and X) or to any of
its excipients (heparin and sodium citrate), known allergy
to heparin or history of heparin-induced thrombocytope-
nia, participation in another clinical study currently or
during the past three months, pregnancy or breast feeding.
Study treatment
Included patients received 25 or 40 IU/kg body weight of
4-factor PCC (Octaplex™, Octapharma AG, Lachen, Swit-
zerland). The study treatment is a human plasma-derived
concentrate that contains vitamin K-dependant clotting
factors II, VII, IX and × as well as protein C and S. The
product also contains heparin and citrate added during
the manufacturing process. The treatment was adminis-
tered immediately in an emergency setting after randomi-
sation and usually before any INR results were available. A
centralised randomisation was done via a dedicated
website. The randomisation was stratified according to the
type of cerebral haemorrhage (intracerebral or subdural).
For each type of cerebral haemorrhage, a randomly per-
muted block scheme was used, with a variable and undi-
sclosed block size. All patients were treated concomitantly
with an intravenous infusion of 5 mg vitamin K. A PCC
rescue dose was administered if the targeted INR (≤1.5)
was not reached, 10 min after the end of the infusion. An
additional infusion of 4-factor PCC was allowed at inter-
vals of 6 h after the administration of the first dose, if the
INR remained >2.
Study outcomes
The primary endpoint of the study was the mean INR at
10 min after the end of 4-factor PCC infusion in each
group. Secondary endpoints included changes in INR,
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prothrombin time (PT), coagulation factors, protein C and
protein S, haematoma growth, clinical status (GCS),
overall clinical response 48 h after the end of infusion and
global clinical outcome assessed using extended Glasgow
Outcome Scale (GOS-E), modified Rankin Scale (mRS)
and Barthel Index (BI) at day 30 after infusion. GOS-E is a
global scale for functional outcome that rates patient sta-
tus into one of five categories: dead, vegetative state, severe
disability, moderate disability or good recovery. The mRS
is a score for measuring the degree of disability or depen-
dence in the daily activities, ranging from 0 (no symptoms)
to 6 (dead). BI is a scale used to measure performance in
basic activities of daily living, ranging from 0 (totally
dependent) to 100 (independent).
Safety endpoints were the occurrence of adverse
events (AE), particularly thromboembolic events, and
changes in vital signs, ECG and laboratory parameters.
The occurrence of any AE - including death, throm-
boembolic complications, intracranial haematoma recur-
rence and allergic reactions- as well as the need for
neurosurgery, were monitored throughout hospital stay
and for 30 days after the infusion.
Laboratory and clinical assessments
At inclusion, all patients underwent a complete clinical
assessment that included medical history, physical exami-
nation and determination of vital signs. Blood samples
were collected to measure INR, PT, coagulation factors II,
VII, IX and X, protein C and protein S prior to infusion,
and at 10 ± 5 min, 1, 3, 6 and 24 h after the end of the
infusion.
Medical imaging was done 48 h after the end of the
infusion or earlier in case of neurological worsening.
Clinical status was evaluated at 1, 24 and 48 h.
Sample size and statistical analysis
All statistical analyses were performed using SAS software
(SAS Institute Inc., Cary, NC, USA). Descriptive statistics
were performed by dose group (25 and 40 IU/kg) for all
parameters and were expressed as percentages or averages
with standard deviation (SD). A descriptive post hoc analy-
sis was performed by infusion speed group (<8 ml/min
and ≥8 ml/min). All efficacy analyses were performed in
intention to treat. Groups were compared using Student’s
t test or Wilcoxon rank sum test for quantitative efficacy
criteria, and Pearson’s c2 or Fisher’s exact test for qualita-
tive efficacy criteria. Safety analyses were presented by
dose group. All statistical tests were two-sided and P <0.05
was considered statistically significant. For sample size
calculation, the following considerations were performed.
The minimal difference expected between the two groups
INR at 10 ± 5 min was 0.4, with a standard deviation of
0.30. Considering an alpha error of 0.05 with a power of
0.95, required sample size for a one-sided t test was 13
patients in each group. However, a larger population size
of 30 patients in each group was included for the compari-
son of baseline and post-treatment values between groups.
Results
Baseline characteristics of study population
Between November 2008 and April 2011, 59 patients
were included and randomised: 29 in the 4-factor PCC
25 IU/kg group and 30 in the 40 IU/kg group. Almost
all patients (n = 53) were admitted in emergency units,
three were admitted in intensive care units, one in a
neurology unit and one in a neurosurgery unit. Prema-
ture withdrawal occurred in fourteen patients, six in the
25 IU/kg group and eight in the 40 IU/kg group. Main
reasons were death (n = 8), patient transfer to another
facility (n = 3), lost to follow-up (n = 2) and discharge
from hospital (n = 1). However, these patients were pre-
sent for the primary criteria evaluation (INR at 10 min
after the end of the infusion). All the patients were
included in the results analysis.
Baseline characteristics of the patients are reported in
Table 1. Overall mean age was 76.4 ± 10.3 years and
71.2% were male patient. Patient characteristics did not
differ between the 25 and 40 IU/kg groups. All patients
had a cardiovascular history. History of neurological and
endocrine disorders was present in 62.7% and 52.5% of
patients, respectively. All patients were treated with vita-
min K antagonist: 85% were under oral anticoagulant
with fluindione, 12% with warfarin sodium and 3% with
acenocoumarol. No marked difference was found
between dose groups.
Median INR at inclusion was 2.8 (range 1.3 to 11.4) and
median GCS was 15 (range 6.0 to 15.0). Mean time from
symptoms onset to diagnosis was 37.6 ± 68.4 hours. Intra-
cranial haemorrhage at inclusion was intracerebral in
36 patients (63.2%) and subdural in 21 patients (36.8%).
Mean haematoma volume was evaluated in 19 patients
and was 20.3 ± 18.5 cm3. Haematoma volume was com-
parable between dose groups.
Treatment infusion
All patients received the allocated dose of 4-factor PCC
at randomisation. The total IU of infused PCC ranged
from 1270 to 4000. Treatment was administered over a
mean infusion time of 10 min (SD 6, range 3 to 30).
The mean administered dose was 1837 IU per patient
(SD 433, range 1270 to 2500) in the 25 IU/kg group and
3017 IU per patient (SD 448, range 2500 to 4000) in the 40
IU/kg group. Mean duration of infusion was significantly
higher in the 40 IU/kg group compared with the 25 IU/kg
group (12.3 ± 7.0 vs. 8.4 ± 4.7 min, P = 0.021). No rescue
dose was administrated. However, only one patient,
belonging to the 40 IU/kg group, received one additional
infusion at 6 h, as the INR exceeded 2 at this time point.
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A total of sixteen patients with subdural haemorrhage
underwent neurosurgical intervention for evacuation of
the haematoma: eight patients in the 25 IU/kg group and
eight in the 40 IU/kg group. There were no significant
differences between dose groups for neurosurgery
characteristics.
Response to treatment
The overall median INR at inclusion was 2.8 (range 1.30 to
11.4). INR was similar in both dose groups at inclusion:
2.5 (range 1.3 to 6.0) for the 25 IU/kg group and 2.8
(range 1.7 to 11.4) for the 40 IU/kg group (P = 0.660). At
10 min after 4-factor PCC infusion, median INR was sig-
nificantly reduced to 1.2 (range 1.0 to 1.5), declining to
≤1.5 in all patients in both groups. A target INR, defined
as INR ≤1.2, was achieved in 44.5% of the 25 IU/kg group
and in 76.0% of the 40 IU/kg group. The overall median
INR values at inclusion, 10 min, 1, 3, 6 and 24 h were 2.8,
1.2, 1.2, 1.2, 1.2 and 1.1, respectively. The benefit of treat-
ment infusion was maintained over time until at least 24 h.
The change over time is shown in Figure 1 in the 25
and 40 IU/kg groups. A significant difference was found
between dose groups: INR in the 40 IU/kg group was
significantly lower than in the 25 IU/kg group at 10 min
(P = 0.001), 1 h (P = 0.001) and 3 h (P = 0.02) after
infusion. These results showed a dose-dependent effect
of 4-factor PCC dose on INR at 10 min.
At 10 min after 4-factor PCC infusion, the INR in
intracerebral haemorrhage and acute subdural haemor-
rhage subgroups was also dependent on the dose. Mean
INR was significantly lower with the 40 IU/kg dose in
intracerebral haemorrhage (1.14 ± 0.09 vs.1.23 ± 0.12 in
the 25 IU/kg group, P = 0.015) and in acute subdural
haemorrhage (1.17 ± 0.11 vs. 1.33 ± 0.11 in the 25 IU/
kg group, P = 0.007).
The impact of 4-factor PCC infusion was also demon-
strated on PT and coagulation factors FII, FVII, FIX, FX,
protein C and protein S. At 10 min after infusion, med-
ian PT value increased from 31.6% at inclusion to
77.0%, FII from 24.0% to 89.0%, FVII from 27.7% to
65.4%, FIX from 44.1% to 79.8%, FX from 12.4 % to
74.0%, protein C from 15.5% to 81.2% and protein S
from 32.0% to 71.0%. This established therapeutic effect
was maintained over time until at least 24 h. Evolution
of coagulation factors is presented in Figure 2 in the 25
and 40 IU/kg groups.
Significant differences were found between dose
groups for PT (P = 0.038), FII (P = 0.001), FX (P
<0.001), protein C (P = 0.002) and protein S (0.043) at
10 min after infusion. At 10 min after infusion, these
values were higher and closer to normal measures in the
40 IU/kg group compared with the 25 IU/kg group. A
dose of 40 IU/kg tended to be more effective in normal-
ising PT and coagulation factors than a 25 IU/kg dose.







Age, years 77.7 ± 9.4 75.2 ± 11.1 0.265
Male gender 19 (65.5) 23 (76.7) 0.344
Body weight, kg 76.9 ± 17.6 76.7 ± 13.5 0.779
Medical history NS
Hypertension 18 (62.1) 21 (70.0)
Atrial fibrillation 18 (62.1) 18 (60.0)
Previous ischemic stroke 3 (10.3) 4 (13.3)
Diabetes mellitus 8 (27.6) 7 (23.3)
Hypercholesterolemia 3 (10.3) 5 (16.7)
Blood pressure, mm Hg
SBP 154 ± 23.4 162 ± 32.7 0.359
DBP 84.1 ± 14.0 86.2 ± 18.3 0.524
Blood glucose, mmol/L 7.7 ± 3.1 7.6 ± 2.4 0.946
Onset to diagnosis, hrs 29.4 ± 51.6 45.8 ± 82.0 0.213
INR 2.9 ± 1.1 3.2 ± 1.9 0.660
GCS 13.3 ± 2.7 13.2 ± 2.8 0.846
Type of intracranial haemorrhage 0.862
Intracerebral haemorrhage 18 (64.3) 18 (62.1)
Acute subdural haemorrhage 10 (35.7) 11 (37.9)
Haematoma volume, cm3 23.8 ± 18.5 16.5 ± 18.9 0.438
Results are expressed as n (%) or mean ± SD. NS, not significant. GCS, Glasgow Coma Scale; INR, international normalised ratio; PCC, prothrombin complex
concentrate.
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Overall clinical outcome
At 48 h, mean haematoma volume was 31.1 ± 31.9 cm3
in the 19 evaluated patients. There was no significant
difference in haematoma volume between dose groups
(33.2 ± 33.9 in the 25 IU/kg vs. 28.7 ± 31.4 in the 40
IU/kg, P = 0.713).
All clinical outcomes at 48 h and day 30 after infusion
are presented in Table 2 for both dose groups.
Mean Glasgow Coma Scale (GCS) was 13.1 ± 3.76 at 48
h and 13.1 ± 3.60 at day 30 after infusion. No difference in
GCS was found between dose groups at 48 h (P = 0.724)
and day 30 (P = 0.858). The overall clinical response was
assessed as excellent in the majority of patients (67.9%
with 95% confidence interval (CI) (55.4 to 8.5)) and
moderate in 24.5% (95% CI (12.9 to 36.1)). Overall clinical
response was similar between dose groups.
At day 30 after infusion, nine patients (16.7%) were
dead or in a vegetative state, twenty-seven (50.0%) with
severe disability, two (3.7%) with moderate disability and
sixteen (29.7%) with good recovery, according to the
GOS-E assessment. Overall, mean mRS was 3.20 ± 2.01
and mean BI was 49.7 ± 41.5 at day 30, meaning that
patients were moderately disabled. No difference in
mRS or in BI was found between dose groups.
Safety
All adverse events (AE) and serious adverse events
(SAE) are presented in Table 3 for the 25 and 40 IU/kg
groups. Within 30 days of follow-up after infusion, ten
patients died: four in the 25 IU/kg group and six in the
40 IU/kg group. No difference was found in mortality
between dose groups (P = 0.731). The causes of death
were as follows: haematoma evolution (n = 3), cerebral
haemorrhage (n = 3), increased intracranial pressure (n
= 1), brain stem ischemia (n = 1), pneumonia (n = 1)
and hyperthermia (n = 1). Two deaths were considered
as unlikely to be related to 4-factor PCC infusion and
the other deaths were considered as unrelated to 4-fac-
tor PCC infusion. Of the two deaths considered unlikely
to be related to PCC infusion, the first patient died 7
days after the infusion from a major persistent





















Figure 1 Changes in mean INR values after 4-factor PCC infusion in 25 and 40 IU/kg groups. *Significant difference with P <0.05. All
patients were present during the 24 h. At inclusion, INR was calculated for 29 patients in the 25 IU/kg group and 30 patients in the 40 IU/kg
group, at 10 min in 27 and 29, at 1 h in 26 and 28, at 3 h in 28 and 30, and at 24 h in 22 and 30, respectively. INR, international normalised
ratio; PCC, prothrombin complex concentrate.
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second died 3 days after the infusion subsequent to a
progression of the haematoma.
Four thrombotic events (TE) occurred during the
study: two ischemic strokes in the 25 IU/kg group, and
pulmonary embolism and phlebitis in the 40 IU/kg
group. The two ischemic strokes occurred 3 and
18 days after the PCC infusion. Pulmonary embolism
and phlebitis occurred 7 and 9 days after the PCC
40 IU/kg (n=30)
25 IU/kg (n=29)
Figure 2 Changes in coagulation factors after 4-factor PCC infusion in 25 and 40 IU/kg groups. *Results are presented as mean and 95%
confidence interval. PCC, prothrombin complex concentrate.
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infusion, respectively. The medical history of these
patients included mainly atrial fibrillation, hypertension,
hypercholesterolemia, obesity, and past thromboembolic
event. These TEs were judged, by the investigators, to
be unrelated to 4-factor PCC infusion.
A further eighteen SAE occurred in fifteen patients:
eight in the 25 IU/kg group and ten in the 40 IU/kg
group. One SAE was considered as unlikely to be related
to the study infusion and the others were considered as
not related to the study infusion. The incidence of AE
and SAE was similar between dose groups.
Post hoc analysis: results by infusion speed
Infusion speed was between 3 and 8 mL min-1 in 20
patients and ≥8 mL min-1 in 39 patients (range: 3.5 to
42.7 mL min-1). The median infusion speed was 10.2
mL min−1 (interquartile range (IQR), 6.9 to 16.0 mL
min−1), equivalent to 254.0 IU min−1 (IQR, 171.9 to
400.0 IU min−1). The respective minimum and maxi-
mum individual patient values were 3.5 and 42.7 mL
min−1. Figure 3 shows the individual patient infusion
speeds, which were between 3 and 8 mL min−1 in 20
patients (34%) and ≥8 mL min−1 in 39 (66%). Infusion
speed exceeded 30 mL min−1 in five patients, of whom
four were enrolled at one study centre.
At baseline, mean INR was 3.35 ± 2.16 in the lower
infusion speed group and 2.93 ± 1.19 in the higher infu-
sion speed group. At 10 ± 5 min after infusion, the
mean INR was significantly reduced to ≤1.5 in both
groups. The occurrence of AEs was 90% (18/20) in
patients with infusion speed between 3 and 8 ml/min vs.
80% (31/39) in patients with infusion speed ≥8 ml/min.
Discussion
This randomised study demonstrates that the 40 IU/kg
dose of 4-factor PCC is more effective than the 25 IU/
kg dose in producing rapid reduction in INR as well as
in replacing coagulation factors. Furthermore, the safety
of the 40 IU/kg dose was found to be similar to that of
the 25 IU/kg dose: no significant AEs were reported in
either group during the immediate post-infusion period
and the longer term safety was supported by a low
death rate and few thrombotic events reported at the
three-month follow-up. Of note, this study showed
lower mortality rate compared with those reported in
previously published papers that approached 60% in







Overall clinical response - verbal rating scale at 48 h 1.000
None 2 (8.0) 2 (7.1)
Moderate 6 (24.0) 7 (25.0)
Excellent 17 (68.0) 19 (67.9)
GCS
At 48 hours 13.1 ± 3.8 13.1 ± 3.8 0.724
At day 30 12.8 ± 4.0 13.3 ± 3.2 0.858
GOS-E at day 30* 0.460
Dead 2 (7.7) 4 (14.3)
Vegetative state 2 (7.7) 1 (3.6)
Lower severe disability 10 (38.5) 11 (39.3)
Upper severe disability 2 (7.7) 4 (14.3)
Lower moderate disability 1 (3.8) 1 (3.6)
Lower good recovery 2 (7.7) 5 (17.9)
Upper good recovery 7 (26.9) 2 (7.1)
mRS at day 30 3.0 ± 2.0 3.4 ± 2.0 0.342
BI at day 30 53.4 ± 40.2 46.0 ± 43.2 0.623
Results are expressed as n (%) or mean ± SD. *GOS-E was performed for a total of 54 patients: 26 patients in the 25 IU/kg group and 28 patients in the 40 IU/kg
group, which explains the difference in number of deaths with that reported in the text (n = 10). BI, Barthel Index; GCS, Glasgow Coma Scale; mRS, modified
Rankin Scale; GOS-E, extended Glasgow Outcome Scale; PCC, prothrombin complex concentrate.








Death 4 (13.8) 6 (20.0) 0.731
Patients with at least one AE 24 (82.8) 25 (83.3) 1.000
Patients with at least one SAE 11 (37.9) 12 (40.0) 0.871
Patients with at least one TE 2 (6.9) 2 (6.7) 1.000
Results are expressed as n (%). AE, adverse effects; PCC, prothrombin complex
concentrate; SAE, serious adverse effects; TE, thrombotic event.
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patients with OAT-associated intracranial haemorrhage
[20]. Regardless of the intracranial haemorrhage type,
subdural or intracerebral haemorrhage, and despite the
rapid infusion speed (maximum infusion speed was 42.7
ml/min); 4-factor PCC infusion was effective and safe.
The content of 4-factor PCC (Octaplex™) used in this
study is well balanced [25]. It contains the vitamin K-
dependent clotting factors II, VII, IX, and × in propor-
tions similar to those occurring in plasma. The other
vitamin K-dependent proteins of the clotting cascade,
protein S and C, are present in therapeutically effective
concentrations to provide antithrombotic effects. Finally,
it contains also small amounts of heparin to prevent
activation of clotting factors.
When PCCs are administered without vitamin K,
usually a rapid normalization of the INR with a rebound
increase is observed 12 to 24 h later; this rebound
increase in the INR is routinely seen when coagulation
factor replacement is not accompanied by vitamin K
[26]. The reason is that the half-life of vitamin K far
exceeds the half-life of the administered PCC. Up to
date, there are no clear recommendations concerning
the dose of vitamin K in the literature (between 5 and
10 mg in French guidelines). Actually, our results
showed that 5 mg of vitamin K is sufficient to maintain
normal coagulation after 6 h in both groups. This role
of vitamin K explains the absence of the statistical dif-
ferences at 6 and 24 h between groups.
There is an ongoing debate about the therapeutic tar-
geted INR in the setting of life-threatening intracranial
haemorrhage. Some guidelines recommend that a target
INR below 1.5 should be achieved, while others advise a
target INR between 1 and 1.2. This is probably of inter-
est for intracranial haemorrhage. All the patients in our
study had achieved an INR ≤1.5 within 10 min after
infusion. However, 76% of the patients in the 40 IU/kg
group reached an INR ≤1.2 as opposed to only 44.5% in
the 25 IU/kg group. The individual levels of clotting fac-
tors as well as protein C and S showed a good and long-
lasting recovery for both dose groups. However, better
recovery was obtained with 40 IU/kg 4-factor PCC for
PT, factors II and X, and protein C. No significant dif-
ference in factor VII and factor IX was found between
the groups. The large extravascular distribution of factor
IX could explain this result. At 24 h, the observed
increase in factors VII and IX could be due to the relay
of vitamin K endogenous synthesis. The relationship
between INR and clotting factors remains unclear.
?? ???? ??????






















Figure 3 Individual patient infusion speed at each study centre. White dots refer to patients in the 25 IU/kg group and black dots refer to
those in the 40 IU/kg group.
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A recent in vitro study showed a correlation between
INR correction and factors replacement after 4-factor
PCC addition [27]. Achieving an INR below 1.5 does
not always seem to be correlated with appropriate fac-
tors replacement. Optimising the therapeutic regimen
towards a more individualized dosing based on weight is
likely to correct INR more accurately and to elevate fac-
tors to appropriately safe levels [27,28].
Baseline large haematoma volume (>30 ml) and haema-
toma growth are predictive of poorer outcome [29]. Data
on haematoma growth in patients treated for VKA-asso-
ciated intracranial haemorrhage are limited. A recent
report indicated that immediate INR reversal with 4-factor
PCC is required to prevent haematoma growth [30]. In our
study, no differences in clinical outcomes including haema-
toma volume and clinical indicators were observed
between the groups, although the higher dose was more
effective on INR normalization. This may be due to the
small sample size and to the study design: although our
data showed a haematoma volume growth, the results are
limited by the small proportion of patients (n = 19) who
underwent imaging at 48 h. Imaging was not imposed by
the protocol and it was performed only in case of neurolo-
gic worsening.
According to the French guidelines, the PCC infusion
was administered in an emergency before any INR
results were available. Results showed that this manage-
ment can prevent wasting time waiting for the initial
INR value and guarantees a complete reversal of antic-
oagulation within 10 min, allowing consequently early
surgery if necessary, as for example in case of subdural
haematoma.
Generally, management of VKA-associated intracranial
haemorrhage depends on the patient’s symptoms severity.
In this study, patients who died within 30 days had received
the infusion in a shorter time lapse after admission than
those who survived (1.25 vs. 2.50 h, P = 0.007). This was
primarily related to the severity of haemorrhage at admis-
sion: patients who died were more severe at admission
(GSC = 10 vs. 14 for survivals, P = 0.001). These data
reflect the real-life practical management of VKA-asso-
ciated intracranial haemorrhage in emergency care.
Patients are managed according to their prognostic factors.
In France, the standard dose indicated for the 4-factor
PCC is 25 IU/kg. A single-centre trial conducted in
18 patients with VKA-associated intracranial haemor-
rhage showed that 20 IU/kg of 4-factor PCC was effec-
tive in reversing the effects of anticoagulation
immediately [24]. Its safety was also demonstrated since
no haemorrhagic or thrombotic adverse effect was
observed [24]. Another study including 60 patients
confirmed the efficacy and safety of the 4-factor PCC at
a median total dose of 41.1 (15.3 to 83.3) IU/kg [23].
There are a few limitations that need to be acknowl-
edged and addressed regarding the present study. First,
patient inclusion was not consecutive because of the
study was conducted in an emergency setting and
because of the availability of the product. Second, a sur-
rogate laboratory primary endpoint was used instead of
a clinical endpoint (for example, death). Other limita-
tions include small sample size and open-label design.
Conclusions
To our knowledge, this is the largest randomised study
that has specifically evaluated the efficacy and safety of a
40 IU/kg dose of 4-factor PCC, compared with a 25 IU/
kg in the management of VKA-associated intracranial
haemorrhage. The dose of 40 IU/kg was more effective
in reducing INR to a value ≤1.2. No difference in TE
was noticed between the groups. However, around 25%
of patients who received the high dose of 40 IU/kg did
not reach the target INR (≤1.2). In a retrospective study,
an INR ≥1.3 was significantly associated with a higher
risk of 30-day mortality in the subgroup of patients with
intracranial haemorrhage [31]. Although this study
design was debatable, this result suggests that normali-
sation of the INR (to value <1.2) could improve the sur-
vival [30]. On the other hand, other authors advocate
for an INR <1.5, meaning that this issue remains unde-
fined [31]. While the impact of the 40 IU/kg dose on
clinical outcomes was not conclusive in our study, our
results support the need for further larger trials to be
conducted to evaluate the impact of high-dose 4-factor
PCC on functional outcomes and mortality.
Key messages
• The 40 IU/kg dose of 4-factor PCC was more effective
in reducing the INR to above 1.2 than the 25 IU/kg
dose.
• A long-lasting benefit on clotting factor elevation
was also observed with the 40 IU/kg dose for PT, factors
II and X, and protein C.
• No difference was found in the haematoma volume
at 48 h after infusion, or in the global clinical outcomes.
This might be related to the study design.
• Safety of the 40 IU/kg dose of 4-factor PCC was
demonstrated. The incidence of thrombotic events or
serious adverse events was similar between groups.
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